Benzinga | Nov 9, 2021 11:05AM EST

Apellis Pharmaceuticals Q3 EPS $(2.28) Misses $(1.75) Estimate, Sales $5.70M Miss $7.22M Estimate

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.75) by 30.29 percent. This is a 27.37 percent decrease over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $5.70 million which missed the analyst consensus estimate of $7.22 million by 21.05 percent. This is a 782.35 percent increase over sales of $646.00 thousand the same period last year.